BioNTech to acquire CureVac for $1.25 billion ... certain of its affiliates and expected to close in 2025 CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into ...

BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is ...

BioNTech (NASDAQ:BNTX) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of ...

(RTTNews) - BioNTech SE (BNTX) and CureVac N.V. (CVAC ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s ...

CureVac (CVAC) stock jumps as BioNTech (BNTX) agrees to acquire in an all-stock deal worth $1.25B. Read more here.

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

BioNTech will present significant clinical trial data at the prestigious ASCO Annual Meeting, highlighting the advancement of its diversified oncology portfolio. The preliminary results for BNT327 ...

BioNTech and Bristol Myers Squibb have announced a partnership for the global co-development and co-commercialization of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, which aims to ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...